Genetic Analysis - Public Comps and Valuation Multiples

Genetic Analysis Overview

About Genetic Analysis

Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world.

Founded

2008

HQ

Employees

Website

genetic-analysis.com

Sectors

Medical Imaging & Diagnostics
HealthTech

Financials

LTM Revenue $1.7M

LTM EBITDA -$0.4M

EV

$3.9M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Genetic Analysis Financials

As of December 2025, Genetic Analysis reported last 12-month revenue of $1.7M and EBITDA of -$0.4M.

In the same period, Genetic Analysis generated $1.2M in LTM gross profit and -$0.9M in net income.

See Genetic Analysis valuation multiples based on analyst estimates

Genetic Analysis P&L

In the most recent fiscal year, Genetic Analysis reported revenue of $1.6M and EBITDA of -$0.9M.

Genetic Analysis expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Genetic Analysis valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$1.7M	XXX	$1.6M	XXX	XXX	XXX
Gross Profit	$1.2M	XXX	$1.3M	XXX	XXX	XXX
Gross Margin	71%	XXX	80%	XXX	XXX	XXX
EBITDA	-$0.4M	XXX	-$0.9M	XXX	XXX	XXX
EBITDA Margin	-21%	XXX	-58%	XXX	XXX	XXX
EBIT	-$0.9M	XXX	-$1.3M	XXX	XXX	XXX
EBIT Margin	-51%	XXX	-85%	XXX	XXX	XXX
Net Profit	-$0.9M	XXX	-$1.5M	XXX	XXX	XXX
Net Margin	-52%	XXX	-93%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Genetic Analysis including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $1.7M. EBITDA for the last twelve months was -$0.4M. In the most recent fiscal year, Genetic Analysis achieved $1.6M in revenue and -$0.9M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$1.7M	Analyst estimates available to subscribers	$1.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$1.2M	Analyst estimates available to subscribers	$1.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	71.4% gross margin	Analyst estimates available to subscribers	80.4% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$0.4M	Analyst estimates available to subscribers	-$0.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-20.6% EBITDA margin	Analyst estimates available to subscribers	-57.7% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$0.9M	Analyst estimates available to subscribers	-$1.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-51.4% EBIT margin	Analyst estimates available to subscribers	-85.2% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$0.9M	Analyst estimates available to subscribers	-$1.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-52.0% net profit margin	Analyst estimates available to subscribers	-93.0% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Genetic Analysis

This financial data table provides comprehensive performance metrics for Genetic Analysis, a company based in Sweden. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Genetic Analysis generated $1.7M in revenue over the last twelve months.
The company achieved -$0.4M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $1.2M.
Net income over the last twelve months reached -$0.9M.

Fiscal Year Performance

In the most recent fiscal year, Genetic Analysis reported $1.6M in total revenue.
Fiscal year EBITDA was -$0.9M.
The company maintained a gross profit margin of 80.4% in the most recent fiscal year.
EBITDA margin for the fiscal year was -57.7%.
Net profit margin reached -93.0% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Genetic Analysis. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Genetic Analysis Stock Performance

Genetic Analysis has current market cap of NOK 49.7M (or $5.0M), and EV of NOK 39.1M (or $3.9M).

Market Cap Evolution

Genetic Analysis Stock Data

As of December 31, 2025, Genetic Analysis's stock price is NOK 1 (or $0).

See Genetic Analysis trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$3.9M	$5.0M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Genetic Analysis Valuation Multiples

Genetic Analysis's trades at 2.5x EV/Revenue multiple, and -4.3x EV/EBITDA.

See valuation multiples for Genetic Analysis and 15K+ public comps

Genetic Analysis Financial Valuation Multiples

As of December 31, 2025, Genetic Analysis has market cap of $5.0M and EV of $3.9M.

Equity research analysts estimate Genetic Analysis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Genetic Analysis has a P/E ratio of -5.5x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$5.0M	XXX	$5.0M	XXX	XXX	XXX
EV (current)	$3.9M	XXX	$3.9M	XXX	XXX	XXX
EV/Revenue	2.2x	XXX	2.5x	XXX	XXX	XXX
EV/EBITDA	-10.8x	XXX	-4.3x	XXX	XXX	XXX
EV/EBIT	-4.3x	XXX	-2.9x	XXX	XXX	XXX
EV/Gross Profit	3.1x	XXX	n/a	XXX	XXX	XXX
P/E	-5.5x	XXX	-3.4x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-3.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Genetic Analysis Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Genetic Analysis Margins & Growth Rates

Genetic Analysis's last 12 month revenue growth is 65%

Genetic Analysis's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.

Genetic Analysis's rule of 40 is -62% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Genetic Analysis's rule of X is 142% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Genetic Analysis and other 15K+ public comps

Genetic Analysis Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	65%	XXX	35%	XXX	XXX	XXX
EBITDA Margin	-21%	XXX	-58%	XXX	XXX	XXX
EBITDA Growth	-94%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-62%	XXX	7%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	142%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	3%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	166%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial